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1. INTRODUCTION {#mgg31118-sec-0005}
===============

Rare syndromes are disorders affecting a scarce number of individuals in the world (Schieppati, Henter, Daina, & Aperia, [2008](#mgg31118-bib-0078){ref-type="ref"}). The low number of patients or resources makes it difficult to detect the molecular cause of these conditions (Daneshjoo & Garshasbi, [2018](#mgg31118-bib-0019){ref-type="ref"}). Instead, increasing knowledge in molecular biology in addition to using cutting‐edge technologies such as next‐generation sequencing (NGS) methods has enabled us to detect genetic defects causing some of the rare syndromes such as pycnodysostosis (PDO). The evident phenotype of PDO affecting the skeletal system is short stature (SS), and initially, based on this feature we selected the patient to detect the possible genetic cause(s).

We diagnosed a patient suspected of PDO as a rare autosomal recessive disease (OMIM 265800) (Figure [1](#mgg31118-fig-0001){ref-type="fig"}a). Although the first case of this disease was described in 1923 by Sedano, Gorlin, and Anderson ([1968](#mgg31118-bib-0080){ref-type="ref"}), since 1962 to now, less than 200 cases have been detected or reported (Naeem, Sheikh, & Ahmad, [2009](#mgg31118-bib-0062){ref-type="ref"}). Thus, this disease is categorized as a rare disease showing an obvious SS phenotype. The universal prevalence of PDO is estimated to be 1 to 1.7 per million with equal sex distribution (Xue et al., [2011](#mgg31118-bib-0094){ref-type="ref"}). Besides SS, the most common features of PDO are increased bone density of long bones, pathological fractures with poor healing, open fontanels, stubby hands and feet with dystrophic nails, and to some extent the obtuse mandibular angle (Xue et al., [2011](#mgg31118-bib-0094){ref-type="ref"}).

![(a) This pedigree is comprised of four generations. The arrow appoints the proband of the family. The genetic status is shown as heterozygote: W/c.905G\>A or homozygote: c.905G\>A/c.905G\>A; in this pedigree, white symbols: unaffected; red symbol: affected; squares: men; circles: females; parallel lines: consanguineous marriage, W: wild‐type allele. (b) Schematic genetic and protein maps of the *CTSK* gene (NM_000396.3). c.905G\>A variant is located in exon 8, which encodes the mature domain of CTSK protein. Similar to other most papain‐like cysteine proteases, CTSK contains 329 amino acids that can be categorized in three distinct sections: a 15‐amino acid preregion, a 99‐amino acid proregion, and a 215‐amino acid mature active enzyme (Toral‐López et al., [2011](#mgg31118-bib-0088){ref-type="ref"}). The low‐PH environment changes inactive CTSK to the active form by the removal of the N‐terminal proregion. (c) UCSC database used to show the conservation of specific nucleotide (G; highlighted as red) including the variant site in vertebrates, particularly in primates. The amino acid sequence of CTSK colored based on conservation scores by the ConSurf database. Scores ranged from 1 to 9, where a score of 9 represented a highly conserved residue. ConSurf demonstrates evolutionary conservation profiles for proteins of known/unknown structure according to the phylogenetic relations between homologous sequences as well as amino acid\'s structural and functional importance. (d) The 3D structure of CTSK is shown. The picture was rendered with PyMOL (v.0.99rc6). The original site of Trp302 is emphasized by a highlighted zone and locally zoomed](MGG3-8-e1118-g001){#mgg31118-fig-0001}

Various mutations in *CTSK* gene have been reported in PDO patients which most of these mutations occur in the mature domain of CTSK protein (Xue et al., [2011](#mgg31118-bib-0094){ref-type="ref"}) (Figure [1](#mgg31118-fig-0001){ref-type="fig"}b); almost 70% of the mutations have been identified in the mature domain of CTSK, 24.24% in the proregion, and 6.06% in the preregion (Xue et al., [2011](#mgg31118-bib-0094){ref-type="ref"}). The *CTSK* gene (NM_000396.3) spans around 12 kb and contains 8 exons (Figure [1](#mgg31118-fig-0001){ref-type="fig"}b). The encoded protein, CTSK or cathepsin K, is a member of the papain‐like cysteine protease family, and there is a high similarity between this protein and other cathepsins such as S and L (Gelb, Shi, Chapman, & Desnick, [1996](#mgg31118-bib-0030){ref-type="ref"}). *CTSK* is highly expressed in osteoclasts (Xue et al., [2011](#mgg31118-bib-0094){ref-type="ref"}), and its mRNA is detectable in macrophages and bone marrow‐derived dendritic cells (Asagiri et al., [2008](#mgg31118-bib-0005){ref-type="ref"}; Honey & Rudensky, [2003](#mgg31118-bib-0040){ref-type="ref"}). Additionally, cathepsin K plays a vital role in osteoclast‐mediated bone resorption by degenerating the bone matrix proteins, such as type I collagen, osteopontin, and osteonectin (Hou et al., [1999](#mgg31118-bib-0042){ref-type="ref"}; Mujawar et al., [2009](#mgg31118-bib-0061){ref-type="ref"}). In a nutshell, impairment of CTSK‐mediated osteoclast apoptosis/senescence may also be responsible for the higher bone density, which is a hallmark feature in patients affected by PDO (Chen et al., [2007](#mgg31118-bib-0016){ref-type="ref"}).

In the present study, the main object was to resolve the genetic diagnosis of SS phenotype in an Iranian male patient with normal parents. By applying whole‐exome sequencing (WES), a novel variant, p.(Trp320\*), in the *CTSK* gene was identified. The physical assessments and medical evaluations confirmed the PDO due to the novel identified variant in this family. According to the American College of Medical Genetics and Genomics‐the Association for Molecular Pathology (ACMG‐AMP) variant interpretation guidelines (Biesecker & Harrison, [2018](#mgg31118-bib-0010){ref-type="ref"}; Oza et al., [2018](#mgg31118-bib-0068){ref-type="ref"}), this variant could be classified as a likely pathogenic variant, albeit functional studies to further confirm the pathogenicity of the variant in appropriate animal models will be recommended.

2. MATERIALS AND METHODS {#mgg31118-sec-0006}
========================

2.1. Editorial policies and ethical considerations {#mgg31118-sec-0007}
--------------------------------------------------

The study protocol was approved by the local medical ethics committee of Tarbiat Modares University, Tehran, Iran. A written informed consent was obtained from all subjects before applying enrollment in this study. The family also provided written informed consent for publication of their pertinent images included in this paper. All of the patient\'s clinical information and the medical histories were collected at the Dr. Azimy Genetic Center, Arak, Iran.

2.2. Subject and clinical investigations {#mgg31118-sec-0008}
----------------------------------------

We enrolled 3 members of the family in our study (Figure [1](#mgg31118-fig-0001){ref-type="fig"}a). The consanguineous family, originating from Arak province of Iran, was suspected to pycnodysostosis. The family was ascertained for the present study, and the affected subject underwent meticulous medical records including a comprehensive physical examination, bone density testing, and radiography tests. Some of the important clinical indices used in this study are summarized in Table [1](#mgg31118-tbl-0001){ref-type="table"}.

###### 

Clinical features of the patient in the family

  Features                                                        IV.1
  --------------------------------------------------------------- -----------------------------------------------------------------
  Age at initial assessment/age at molecular assessment           17/20
  Gender                                                          Male
  Father age at conception                                        31
  Weight at birth                                                 Below 5th percentile (3.1 ± 0.01 kg)
  Height at birth                                                 Below 5th percentile (45.2 ± 0.10 cm)
  Head circumference at birth                                     36.3 ± 0.10 cm
  Height at assessment                                            137 ± 0.10 cm
  Weight at assessment                                            34 ± 0.01 kg
  Sexual maturity rating                                          Stage IV
  Short stature (\<150 cm)                                        Observed
  Increase in bone density                                        Observed
  Open fontanels and sutures                                      Open sutures of anterior fontanel and closed posterior fontanel
  Frontal and parietal bossing                                    Observed
  Fractures                                                       Developed easy fractures for four times
  Obtuse mandibular angle                                         Observed
  Short fingers and hypodontia                                    Observed
  Stubby hands and feet with osteolysis of the distal phalanges   Observed
  Prominent eyes with bluish sclerae                              Observed
  Hypoplastic maxilla                                             Observed
  Grooved palate                                                  Observed
  Scoliosis                                                       Scoliosis was evident in the thoracic region
  Dysplastic nails                                                Dysplastic nails were evident in this patient
  Nonpneumatized paranasal sinuses                                Not applicable
  Prominent nose                                                  Observed
  Macrocephaly                                                    Observed
  Asymmetric skull                                                Observed
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2.3. DNA extraction {#mgg31118-sec-0009}
-------------------

To apply genetic tests, around 10 ml of blood samples was taken from the patient and his parents, and then, genomic DNA was isolated from the samples by Roche DNA Extraction Kit (Cat. No. 11814770001, Roche Life Science). Thence, DNA concentrations were measured by Thermo Scientific™ Nanodrop 2000 (Thermo Fisher Scientific).

2.4. Whole‐exome sequencing {#mgg31118-sec-0010}
---------------------------

About 1 μg of genomic DNA sample of the patient (IV.I) was subjected to high‐throughput sequencing. RNA capture baits against approximately 60 Mb of the Human Exome (targeting \> 99% of regions in CCDS, RefSeq, and Gencode databases) were used to enrich regions of interest from fragmented genomic DNA with Agilent\'s SureSelect Human All Exon V6 kit. The generated library was sequenced on an Illumina platform to obtain an average coverage depth of approximately 100×. Typically, around 97% of the targeted bases were covered \>10×.

2.5. Bioinformatics analysis {#mgg31118-sec-0011}
----------------------------

An end‐to‐end in‐house bioinformatics pipeline including base calling, alignment of reads to GRCh37/hg19 genome assembly, primary filtering of low‐quality reads and probable artifacts, and subsequent annotation of variants was applied. The reads were aligned to the reference genome (hg19/NCBI37.1) with SNP & Variation Suite version 8.0 (SVS v8.0) and DNASTAR Lasergene12 (DNASTAR Inc.). Small indel detection was used with the Unified Genotyper tool from GATK tools in Galaxy online database (<http://www.usegalaxy.org>). The missense, nonsense, silent, and indel variant rates were estimated by Galaxy online tool and finally were confirmed by Ivariantguide^®^ (Chaudhry & Tainsky, [2019](#mgg31118-bib-0015){ref-type="ref"}).

Regarding the pedigree and inheritance mode, we assumed that the variant(s) might be inherited as homozygous manner and we hereby excluded the heterozygous variants, and then, several filtering steps were applied to prioritize all variants: (a) Variants in dbSNP132 (<https://www.ncbi.nlm.nih.gov/projects/SNP>), 1000 Genomes Project (Siva, [2008](#mgg31118-bib-0082){ref-type="ref"}), and GnomAD (Karczewski & Francioli, [2017](#mgg31118-bib-0046){ref-type="ref"}) with allele frequencies more than 1% were excluded. (b) The rest of the variants underwent further exclusion in the Exome Sequencing Project (ESP) (<http://evs.gs.washington.edu/EVS>) and Exome Aggregation Consortium (ExAC) database. (c) The intragenic, intronic, untranslated regions (UTRs), and synonymous variants were excluded from later analysis. (d) The SIFT (Ng & Henikoff, [2003](#mgg31118-bib-0063){ref-type="ref"}), Provean (Choi & Chan, [2015](#mgg31118-bib-0018){ref-type="ref"}), and MutationTaster (Schwarz, Rödelsperger, Schuelke, & Seelow, [2010](#mgg31118-bib-0079){ref-type="ref"}) were used to predict the pathogenicity/prioritization of candidate variants (Table [2](#mgg31118-tbl-0002){ref-type="table"}). To be on the safe side, the filtering was applied with assuming the heterozygous mode of inheritance, but this did not lead to candidate variant(s) in this family.

###### 

Several online databases that used to confirm the pathogenicity of the variant in *CTSK*

  Variant        Gene     Zygosity   MutationTaster   EXAC   SIFT              1K Genome   Iranome    PROVEAN   ENTPRISE‐X                 
  -------------- -------- ---------- ---------------- ------ ----------------- ----------- ---------- --------- ------------ ------------- -------------
  p.(Trp320\*)   *CTSK*   Hom.       Het.             Het.   Disease causing   N.R         Damaging   N.R       N.R          Deleterious   Deleterious

Abbreviations: Het, Heterozygote; Hom, Homozygote; N.R, Not Reported.
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To narrow down the list of candidate variants as much as possible, we used Phenolyzer (Yang, Robinson, & Wang, [2015](#mgg31118-bib-0095){ref-type="ref"}), Face2Gene (<https://www.face2gene.com/>), and Varcards (Li et al., [2017](#mgg31118-bib-0056){ref-type="ref"}). All suspected pathogenic variants were double‐checked in HGMD^®^ (Stenson et al., [2003](#mgg31118-bib-0084){ref-type="ref"}) and ClinVar (Landrum et al., [2015](#mgg31118-bib-0051){ref-type="ref"}).

ConSurf server (Glaser et al., [2003](#mgg31118-bib-0032){ref-type="ref"}) and UCSC database (Karolchik et al., [2003](#mgg31118-bib-0047){ref-type="ref"}) were applied to provide an evolutionary conservation profile for CTSK protein and DNA sequence, respectively, to better predict the potential disrupting effects of the variant (Figure [1](#mgg31118-fig-0001){ref-type="fig"}c and d). For further consideration, the frequency of the variant was checked out on Iranome as the local database (Fattahi et al., [2019](#mgg31118-bib-0025){ref-type="ref"}) (Figure [2](#mgg31118-fig-0002){ref-type="fig"}a). All information related to the in silico predictions such as allele frequency, cosegregation results, and pathological predictions is summarized in Table [2](#mgg31118-tbl-0002){ref-type="table"}.

![(a) Schematic representation of filtering strategies exploited in this research. For more investigation, the filtering steps evaluated by regard to this fact that the disease could be engendered by autosomal dominant; however, we could detect no relevant variant according to this supposition. (b) Sequence chromatogram shows a homozygous state of the nucleotide sequence of c.905G\>A. (c) Radiography shows the large head circumstance, obtuse mandibular angle, and scoliosis, which was evident in the patient. (d) Short fingers revealed by X‐ray and the dysplastic flat nails were evident in the patient (For detailed, please refer to Figure [S1](#mgg31118-sup-0001){ref-type="supplementary-material"})](MGG3-8-e1118-g002){#mgg31118-fig-0002}

2.6. Segregation analysis {#mgg31118-sec-0012}
-------------------------

Sanger sequencing in forward and reverse directions was performed to validate the candidate variant, and then, segregation analysis was performed in the family. The primers were designed by Primer3.0 (<http://bioinfo.ut.ee/primer3-0.4.0>) Web‐based server (Table [S1](#mgg31118-sup-0002){ref-type="supplementary-material"}). The lack of SNPs in the genomic region corresponding to the 3′ ends of primers was inspected by looking through the dbSNP database. The specificity of primers was checked by the in silico‐PCR tool in UCSC genome browser (<https://genome.ucsc.edu/cgi-bin/hgPcr>) and Primer blast on NCBI genome browser (<https://www.ncbi.nlm.nih.gov/tools/primer-blast/>). Finally, polymerase chain reaction (PCR) was performed in standard conditions, and then, PCR products were sequenced by ABI 730XL, using the conventional capillary system. Chromatograms were analyzed by GenomeCompiler online tool (<http://www.genomecompiler.com>) and Mutation Surveyor v.3.24 (Softgenetics) to identify the alternation. Variants were annotated based on the standards of the Human Genome Variation Society (HGVS) nomenclature (den Dunnen et al., [2016](#mgg31118-bib-0021){ref-type="ref"}).

2.7. Three‐dimensional structure modeling {#mgg31118-sec-0013}
-----------------------------------------

The identified variant, p.(Trp320\*), is located in the mature domain of cathepsin K (Figure [1](#mgg31118-fig-0001){ref-type="fig"}e). The protein families and domains were analyzed using ScanProsite (Gattiker, Gasteiger, & Bairoch, [2002](#mgg31118-bib-0029){ref-type="ref"}), and sequence alignments were recruited by using ClustalW (<http://www.ebi.ac.uk/clustalw>). The protein structures and possible effects of the novel variant on cathepsin K were analyzed by PyMOL (DeLano, [2002](#mgg31118-bib-0020){ref-type="ref"}) after building the PDB structure file based on the Phyre2 (Kelley, Mezulis, Yates, Wass, & Sternberg, [2015](#mgg31118-bib-0048){ref-type="ref"}) and SWISS‐PROT (Bairoch & Boeckmann, [1992](#mgg31118-bib-0007){ref-type="ref"}). The RAMPAGE online tool (<https://www.mordred.bioc.cam.ac.uk/~rapper/rampage.php>) was applied to check out the detailed residue‐by‐residue stereochemical quality on the basis of a Ramachandran plot to know whether the modeled structure was acceptable.

3. RESULTS {#mgg31118-sec-0014}
==========

3.1. Clinical findings {#mgg31118-sec-0015}
----------------------

The patient, 18‐year‐old male, showed typical clinical features of the hereditary PDO, for example, abnormal skeletal system, scoliosis, SS with skeletal dysplasia, increased density of bones, open sutures of anterior fontanel and closed posterior fontanel, history of easy fractures for four times, frontal bossing, micrognathia, asymmetric skull and macrocephaly, short fingers with dysplastic flat nails, midface retrusion, and prominent nose. In addition, dental abnormalities including severe crowding, poor oral hygiene, periodontal problems, delayed exfoliation of primary teeth, an eruption of permanent teeth, enamel hypoplasia, obliteration of pulp chambers, and hypercementosis were evident. The patient\'s radiographs exhibited an obtuse mandibular angle, the general increase in bone density, and open fontanels and sutures (Figure [2](#mgg31118-fig-0002){ref-type="fig"}c).

In the assessment period, Tanner Stages, also known as Sexual Maturity Rating, was examined as stage IV. The history of short stature and growth retardation noted at 3 years of age, while at birth time weight (3.1 ± 0.01 kg; reference in an Iranian population: 3.26 ± 0.60 kg) and height (45.2 ± 0.10 cm; reference in an Iranian population: 51.9 ± 3.59 cm) were below 5th percentile in comparison with the normal values (Heydari, Emamghoreishi, & Amini, [2009](#mgg31118-bib-0039){ref-type="ref"}) and head circumference (36.3 ± 0.1 cm; reference in an Iranian population: 35.13 ± 1.45 cm (Esmaeili & Esmaeili, [2015](#mgg31118-bib-0024){ref-type="ref"})), was above 95th percentile. Further bone evaluations showed increased bone density with the preservation of growth plate and sign of old fractures. Other important detected clinical features are summarized in Table [1](#mgg31118-tbl-0001){ref-type="table"}. In addition to obvious dysplastic nails, radiographic examination of the index case verified the increased bone density and short fingers in comparison with the average values (Figure [2](#mgg31118-fig-0002){ref-type="fig"}d).

Regarding the pedigree provided, the parents were consanguineous. Further laboratory analysis affirmed normal values for leukocyte and thrombocyte counts, plasma phosphate, and alkaline phosphatase. Additionally, no obvious phenotypic abnormality was observed in the parents.

3.2. Genetic analysis {#mgg31118-sec-0016}
---------------------

To elucidate the underlying genetic cause(s), genomic DNA was obtained from the patient and analyzed by solo clinical WES, and finally, p.(Trp320\*) variant was confirmed by Sanger sequencing (Figure [2](#mgg31118-fig-0002){ref-type="fig"}b).

In the patient, the detected SNVs and deletion/insertions were analyzed by several filtering steps. In total, 91,395 variants were found by WES in the proband after alignment and SNV calling. By applying several exclusion processes such as base quality filtering, and frequency in dbSNP132, 1000 Genomes Project, ESP, GnomAD, and ExAc databases, 51 variants were identified. These variants then prioritized based on the patient\'s phenotypes.

Eventually, regarding the phenotypes by utilizing CentoMD (Trujillano), ClinVar, phenolyzer (Yang et al., [2015](#mgg31118-bib-0095){ref-type="ref"}), Face2Gene, Human phenotype ontology (Robinson et al., [2008](#mgg31118-bib-0074){ref-type="ref"}), and Varcards, only one relevant variant was identified. Consequently, the samples from the available members of the family were subjected to Sanger sequencing and segregation of the candidate nonsense variant of the *CTSK* gene was confirmed (Figure [2](#mgg31118-fig-0002){ref-type="fig"}b). Finally, we classified the variant based on ACMG‐AMP guidelines (<http://wintervar.wglab.org>) into a likely pathogenic variant.

To caveat, besides considering autosomal recessive inheritance mode for this family, we considered autosomal dominant inheritance, but this analysis did not result in any candidate variant. All details of filtering steps are accessible in Table [3](#mgg31118-tbl-0003){ref-type="table"}, and all statistics regarding the variants are given in Table [S2](#mgg31118-sup-0002){ref-type="supplementary-material"}.

###### 

The number of variants identified in patients through WES

  Patient                                    IV.I
  ------------------------------------------ --------
  Total variants                             91,395
  Variants after base quality filtering      77,909
  Homozygous variants                        31,383
  Nonsynonymous/indel/splice site variants   8,928
  Novel variants (dbSNP132/1000GP queried)   51
  Genes with plausible disease association   6
  Phenotype analysis                         1
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3.3. In silico predictions {#mgg31118-sec-0017}
--------------------------

We used RAMPAGE online tool to show the detailed residue‐by‐residue stereochemical quality of CTSK in accordance with the Ramachandran plot. The structural model of CTSK indicated almost 98.1% of residues in the most favored regions, around 0.7% of residues in allowed regions, and only 0.2% of residues in the outlier regions, which suggested that the modeled structure of this protein was acceptable.

Various in silico predictor databases such as SIFT, PolyPhen‐2, MutationTaster, Provean, and ENTPRISE‐X (Zhou, Gao, & Skolnick, [2018](#mgg31118-bib-0097){ref-type="ref"}) were used to evaluate the possible pathogenicity of the variant. All detailed results are described in Table [2](#mgg31118-tbl-0002){ref-type="table"}.

4. DISCUSSION {#mgg31118-sec-0018}
=============

Bone development is a complex process in which a balance between bone formation and resorption is delicately maintained (Razmara et al., [2019](#mgg31118-bib-0071){ref-type="ref"}). In fact, osteoblasts and also osteoclasts have an important hand in this process, and any perturbation influencing this procedure causes multitudinous genetic bone diseases ranging from osteoporosis to osteopetrosis (Tanaka, Nakayamada, & Okada, [2005](#mgg31118-bib-0085){ref-type="ref"}). To date, many genes have been identified related to skeletal abnormalities (Table [S3](#mgg31118-sup-0002){ref-type="supplementary-material"}), although the molecular and cellular basis of a great number of skeletal genetic disorders is still uncertain and this knowledge gap can be filled by using advanced technologies such as NGS, which has importantly expedited the detection of responsible genetic causes. Among NGS techniques, WES has been developed into a robust and cost‐effective tool to identify the genetic cause in rare diseases (Razmara & Garshasbi, [2018](#mgg31118-bib-0072){ref-type="ref"}). Using WES, we succeeded to identify a novel variant in the *CTSK* gene in an Iranian male patient presenting SS phenotype. We also provided evidence supporting the causative role of homozygous p.(Trp320\*) in index case using in silico predictions. Nevertheless, the messy reality of unknown significant variants is not going away anytime soon, much as clinicians, geneticists, and patients might wish it would; in this study by applying different stages of filtering, 51 unknown significant variants were detected in the patient from which 6 genes were plausible showing an association with reported skeletal diseases. To narrow down as much as possible, we used the clinical data of the patient in various databases, for example, Face2gene (Table [3](#mgg31118-tbl-0003){ref-type="table"}). This helped us to decrease the number of candidate variants to only one variant, thence confirmed by Sanger sequencing. The c.905G\>A variant in the *CTSK* gene segregated with the condition in the family.

Cathepsin K deficiency does not influence on the function of osteoclast‐mediated extracellular acidification (Chen et al., [2007](#mgg31118-bib-0016){ref-type="ref"}), whereas *CTSK* mutations have been detected to halter the ability of osteoclasts to degrade collagen rather than demineralize the extracellular matrix. Furthermore, cathepsin K may also function as a potential regulator of apoptosis and senescence, controlling osteoclast numbers in vivo (Chen et al., [2007](#mgg31118-bib-0016){ref-type="ref"}). Studies on the *Ctsk* ^−/−^ mice have revealed that the number of chondroclasts and osteoclasts is increased in joint tissues of the mice, whereas osteoclast numbers are increased in the mouse bones (Soki et al., [2018](#mgg31118-bib-0083){ref-type="ref"}). Similarly, some scrapes of evidence showed that the deletion of *CTSK* in osteoclasts enhances bone formation in vivo (Lotinun et al., [2013](#mgg31118-bib-0059){ref-type="ref"}). These data can justify the increased bone density in the patients affected by pycnodysostosis.

The clinical presentation of the patient in the family was originally described as SS and solo‐WES detected a novel variant in the *CTSK* gene. The hallmark features of this disease such as increased bone density, frontal bossing, micrognathia, prominent nose, short stature, delayed abnormal tooth eruption, and fragility fractures were observed in the index case. Indeed, one of the two original descriptions of PDO in 1962 named it an osteopetrosis variant (Pangrazio et al., [2014](#mgg31118-bib-0069){ref-type="ref"}). However, PDO is usually a progressive but relatively benign condition. The applied clinical assessments confirmed that the patient is affected by pycnodysostosis, not osteopetrosis. Evaluation of the radiographs available for the patient showed the obtuse mandibular angle on a craniolateral view and absence of acroosteolysis of the hands (Figure [2](#mgg31118-fig-0002){ref-type="fig"}c). Moreover, it seems that haploinsufficiency, a dominant phenotype in diploid organisms that are heterozygous for a loss‐of‐function allele, is not responsible for the impairment of *CTSK*, because none of the parents showed pertinent clinical symptoms. Thus, not only did this help us to exclude the osteopetrosis but also it provided cogent evidence of pycnodysostosis in the index case.

The p.(Trp320\*) variant may lead to the production of a truncated protein with loss of downstream functional domain in the cell; as a result, cells should forestall this process by nonsense‐mediated decay response (NMD response), which is increasingly appreciated as one of the central mechanisms of RNA surveillance, with a great role in the physiological control of gene expression. Chen et al. showed that a deficiency of cathepsin K prevents inflammation and bone erosion in rheumatoid arthritis and periodontitis and reveals its shared osteoimmune role (Hao et al., [2015](#mgg31118-bib-0036){ref-type="ref"}). Based on the identified variant, we propose NMD or loss of downstream functional domain as judicial mechanisms of pathogenesis of p.(Trp320\*) variant in the patient, but more studies need to unearth the exact molecular mechanisms that contribute to the pathogenicity.

Additionally, it has been shown that cathepsin K plays a role in hormone activation or degradation (Tepel, Bromme, Herzog, & Brix, [2000](#mgg31118-bib-0086){ref-type="ref"}), glucose metabolism (Yang et al., [2008](#mgg31118-bib-0096){ref-type="ref"}), and pathogenesis of obesity (Xiao et al., [2006](#mgg31118-bib-0093){ref-type="ref"}). Thus, the identification of novel functional variants can broaden the horizons toward understanding the mechanisms in which cathepsin K plays roles.

To conclude, our results indicate that the novel nonsense variant, c.905G\>A; p.(Trp320\*), in the *CTSK* gene (NM_000396.3) might be the genetic cause of pycnodysostosis. The putative variant meets the criteria of being pathogenic, but we firmly advise applying functional analysis with animal models to inspect the distinctive pathological roles of this variant.

5. CONCLUSION {#mgg31118-sec-0019}
=============

In summary, we report the *CTSK* variant p.(Trp320\*), which is associated with PDO in a male Iranian patient. We hope that this identification may also yield new insights into the mechanisms of human bone disease, especially in relation to metabolic alterations occurring during this process. We also suggest doing functional analysis by applying appropriate animal models to decipher the mechanism of pathogenesis of the variant prior to using in genetic counseling.
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